Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 32.17% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -74.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.51% |
| Dec 31, 2025 | 41.85% |
| Sep 30, 2025 | -52.12% |
| Jun 30, 2025 | 81.03% |
| Mar 31, 2025 | 33.12% |
| Dec 31, 2024 | -36.16% |
| Sep 30, 2024 | -52.81% |
| Jun 30, 2024 | 80.92% |
| Mar 31, 2024 | 33.60% |
| Dec 31, 2023 | -35.74% |
| Sep 30, 2023 | 41.08% |
| Jun 30, 2023 | -23.96% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | -41.57% |
| Sep 30, 2022 | 211.81% |
| Jun 30, 2022 | 27.16% |
| Mar 31, 2022 | -43.88% |
| Dec 31, 2021 | 49.68% |
| Sep 30, 2021 | -49.25% |
| Jun 30, 2021 | 6.50% |
| Mar 31, 2021 | -66.48% |
| Dec 31, 2020 | 135.89% |
| Sep 30, 2020 | -64.96% |
| Jun 30, 2020 | 36.47% |
| Mar 31, 2020 | -261.27% |
| Dec 31, 2019 | 149.07% |
| Sep 30, 2019 | -27.96% |
| Jun 30, 2019 | -106.48% |
| Mar 31, 2019 | 106.99% |
| Dec 31, 2018 | 34.07% |
| Sep 30, 2018 | -30.93% |
| Jun 30, 2018 | 2.93% |
| Mar 31, 2018 | -6.43% |
| Dec 31, 2017 | 50.02% |
| Sep 30, 2017 | -41.93% |
| Jun 30, 2017 | -21.63% |
| Mar 31, 2017 | -27.23% |
| Dec 31, 2016 | 144.36% |
| Sep 30, 2016 | 139.24% |
| Jun 30, 2016 | 32.61% |
| Mar 31, 2016 | -2.16% |